Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches

Glioblastomas (GBs) are malignant brain tumours with poor prognosis even after aggressive therapy. Programmed cell death-1 (PD-1) immune checkpoint blockade is a promising strategy in many types of cancer, but its therapeutic effects in GB remain low and associated with immune infiltration. Previous...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shuang, Calero-Pérez, Pilar, Arús, Carles, Candiota, Ana Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699815/
https://www.ncbi.nlm.nih.gov/pubmed/33233585
http://dx.doi.org/10.3390/ijms21228775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699815/
https://www.ncbi.nlm.nih.gov/pubmed/33233585
http://dx.doi.org/10.3390/ijms21228775

Ejemplares similares